0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Narrative Review: Paroxysmal Nocturnal Hemoglobinuria: The Physiology of Complement-Related Hemolytic Anemia

Robert A. Brodsky, MD
[+] Article and Author Information

From Johns Hopkins Medical Institutions, Baltimore, Maryland.


Grant Support: From the National Institutes of Health (P01CA70970).

Potential Financial Conflicts of Interest:Consultancies: Alexion Pharmaceuticals. Honoraria: Alexion Pharmaceuticals. Grants received: National Institutes of Health. Patents received: U.S. patent number 6 393 095 B1 for detection of GPI-anchored proteins.

Requests for Single Reprints: Robert A. Brodsky, MD, Division of Hematology, Johns Hopkins Medicine, Ross Research Building Room 1025, 720 Rutland Avenue, Baltimore, MD 21205-2196; e-mail, brodsro@jhmi.edu.


Ann Intern Med. 2008;148(8):587-595. doi:10.7326/0003-4819-148-8-200804150-00003
Text Size: A A A

Dr. Paul Strübing provided one of the earliest descriptions of PNH (14). In 1882, he reported a 29-year-old cartwright who presented with fatigue, abdominal pain, and severe nocturnal paroxysms of hemoglobinuria. Later reports by Marchiafava and Micheli led to the eponym the Marchiafava–Micheli syndrome, but Enneking introduced the term paroxysmal nocturnal hemoglobinuria in 1925 (15).

First Page Preview

View Large
First page PDF preview

Figures

Grahic Jump Location
Figure 1.
Early morning urine sample in a patient with paroxysmal nocturnal hemoglobinuria.
Grahic Jump Location
Grahic Jump Location
Figure 2.
Flow cytometric assay of normal and paroxysmal nocturnal hemoglobinuria granulocytes.

Top. Granulocytes from a normal control participant show bright fluorescein-labeled proaerolysin (FLAER) staining in all cells. Bottom. A patient with paroxysmal nocturnal hemoglobinuria who has a large population of paroxysmal nocturnal hemoglobinuria granulocytes (84% FLAER-negative) and 16% normal granulocytes.

Grahic Jump Location
Grahic Jump Location
Figure 3.
Schematic representation of cell membrane showing transmembrane proteins and glycosylphosphatidylinositol (GPI)–anchored proteins.

The lipid portion of the GPI anchor inserts into the lipid bilayer; no peptide transmembrane portion or cytoplasmic tail is present.

Grahic Jump Location
Grahic Jump Location
Figure 4.
Complement activation: classic, alternative, and lectin binding pathways converge at the point of C3 activation.

The alternative pathway is in a state of continuous activation. The formation of C5 convertase initiates the lytic pathway and leads to the assembly of the membrane attack complex from C5, C6, C7, C8, and multiple C9 proteins. Normally, CD55 inhibits C3 convertases and CD59 blocks incorporation of C9 into the C5b–8 complex. Eculizumab is a humanized monoclonal antibody that binds to C5, thereby preventing the formation of C5a and C5b (the initiating component of the membrane attack complex).

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Eculizumab therapy. Biol Blood Marrow Transplant 2014;20(4):438-9.
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)